Valuation: PYC Therapeutics Limited

Market Cap 1.79B 1.26B 1.09B 1.02B 933M 1.76B 120B 11.98B 4.7B 59.71B 4.72B 4.62B 200B P/E 2026 *
-24.2x
P/E 2027 * -18.4x
Enterprise Value 1.13B 790M 687M 639M 587M 1.11B 75.43B 7.54B 2.96B 37.55B 2.97B 2.9B 126B EV / Sales 2026 *
307x
EV / Sales 2027 * -
Free-Float
70.64%
Yield 2026 *
-
Yield 2027 * -
1 day+7.06%
1 week+7.37%
Current month+7.06%
1 month+18.57%
3 months+51.04%
6 months+20.53%
Current year+9.97%
1 week 1.62
Extreme 1.62
1.85
1 month 1.49
Extreme 1.49
1.85
Current year 1.04
Extreme 1.045
1.85
1 year 0.85
Extreme 0.847
1.85
3 years 0.52
Extreme 0.52
2.1
5 years 0.5
Extreme 0.5
2.1
10 years 0.14
Extreme 0.14
2.1
Manager TitleAgeSince
Chief Executive Officer 42 18/08/2020
Director of Finance/CFO 47 06/07/2026
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 42 29/11/2018
Director/Board Member - 21/09/2025
Chairman 66 17/11/2025
Date Insider Type Main position Quantity % Market Cap.
23/12/25 Free

Chairman

2,000,000 0.3429%
26/11/25 Buy

Chief Executive Officer

133,350 0.0229%
27/02/25
Australia Land Pty Ltd.
BuyCompany 28,000,000 6.0008%
Change 5-day change 1-year change 3-year change Capi.($)
+7.06%+7.37%+50.41%+213.79% 1.17B
+0.43%+1.47%+0.35%+15.84% 48.53B
-1.01%-0.90%+411.96%+472.09% 39.87B
-0.78%+12.96%+28.81%+7.27% 38.68B
-0.85%-3.03%+5.69%+66.52% 35.13B
-1.74%+5.12%+14.44%+44.64% 29.79B
-0.46%-4.04%+36.40%+126.06% 16.11B
+0.37%-3.92% - - 16.08B
+1.20%+2.72%+3.31%+16.75% 13.61B
-2.62%-1.32%-1.73%-34.97% 12.62B
Average -0.07%+1.19%+61.07%+103.11% 25.16B
Weighted average by Cap. -0.76%+2.04%+80.06%+108.72%

Financials

2026 *2027 *
Net sales 3.67M 2.57M 2.24M 2.08M 1.91M 3.61M 246M 24.55M 9.63M 122M 9.67M 9.45M 410M -
Net income -57.43M -40.31M -35.05M -32.62M -29.95M -56.56M -3.85B -385M -151M -1.92B -151M -148M -6.42B -85.75M -60.19M -52.33M -48.7M -44.72M -84.44M -5.75B -574M -225M -2.86B -226M -221M -9.59B
Net Debt -664M -466M -405M -377M -346M -654M -44.51B -4.45B -1.75B -22.16B -1.75B -1.71B -74.31B -579M -406M -353M -329M -302M -570M -38.78B -3.87B -1.52B -19.31B -1.53B -1.49B -64.74B
Logo PYC Therapeutics Limited
PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002).
Employees
5
Date Price Change Volume
03/08/26 A$1.820 +7.06% 2,371,962
31/07/26 A$1.700 +1.49% 665,496
30/07/26 A$1.675 +3.08% 2,778,064
29/07/26 A$1.625 0.00% 1,699,137
28/07/26 A$1.625 -4.13% 697,004
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.700AUD
Average target price
3.752AUD
Spread / Average Target
+120.71%

Quarterly revenue - Rate of surprise